ACCL vs DRMA
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Aug 02, 2026
ACCL
51.2
AI Score
VS
ACCL Wins
DRMA
43.8
AI Score
Investment Advisor Scores
DRMA
44score
Recommendation
HOLD
AI Analyst Insights
AI insights temporarily unavailable
Detailed Metrics Comparison
| Metric | ACCL | DRMA | Winner |
|---|---|---|---|
| Net Income | 1.02M | -1.85M | ACCL |
| Operating Income | 1.08M | -1.93M | ACCL |
| ROE | 46.7% | -28.8% | ACCL |
| ROA | 26.1% | -24.7% | ACCL |
| Total Assets | 3.91M | 7.47M | DRMA |
| Cash | 2.45M | 6.95M | DRMA |
| Current Ratio | 1.82 | 7.66 | DRMA |
Relative Price Performance (Last 90 Days)
ACCL 1M: +32.7%
· 3M: +48.7%
DRMA 1M: -15.2%
· 3M: -14.6%
Current Technical Phase
ACCL
MarkupHold / add on dips
Price above SMA50, rising 50-day trend (13.8% over 20 days), RSI 76
DRMA
NeutralHold
Mixed signals - no dominant trend phase, RSI 39
Fundamentals Snapshot
| Metric | ACCL | DRMA |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 0.0 | -0.8 |
| Trailing P/E | 55.4 | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 0.0% |
| Gross Margin | 0.4% | — |
| Operating Margin | 0.0% | 0.0% |
| EPS | 0.04 | -4.17 |
| Dividend Yield | — | — |
Frequently Asked Questions
Based on our detailed analysis, ACCL is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.
We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.
Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.